RBC Capital Markets Reiterates “Outperform” Rating for Aptose Biosciences Inc. (APTO)
Several other research firms have also commented on APTO. Canaccord Genuity restated a buy rating and set a $7.00 price target on shares of Aptose Biosciences in a research report on Thursday, June 9th. Royal Bank Of Canada restated an outperform rating and set a $23.00 price target on shares of Aptose Biosciences in a research report on Saturday, June 25th. Roth Capital upgraded Aptose Biosciences from a neutral rating to a buy rating and raised their price target for the stock from $4.00 to $8.00 in a research report on Monday, June 13th. Oppenheimer Holdings Inc. restated a buy rating on shares of Aptose Biosciences in a research report on Thursday, June 9th. Finally, Zacks Investment Research lowered Aptose Biosciences from a hold rating to a sell rating in a research report on Friday, August 12th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Aptose Biosciences currently has an average rating of Buy and a consensus price target of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) opened at 2.17 on Tuesday. The firm’s 50-day moving average price is $2.26 and its 200 day moving average price is $2.54. Aptose Biosciences has a 1-year low of $1.92 and a 1-year high of $6.40. The stock’s market cap is $27.98 million.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 19.43% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.